Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurisco Pharmaceutical CoSHSE:605116 +0.15%79 PS Ratio is 4.91 as of Aug. 04, 2026, which is 34% below its 10-year median of 7.49. GuruFocus rates SHSE:605116 with a GF Score™ of 79/100 and a GF Value™ of ¥29.10 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 931 Biotechnology companies, Aurisco Pharmaceutical Co ranks better than 65.52% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aurisco Pharmaceutical Co's share price is ¥20.22.
Aurisco Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥4.12. Hence, Aurisco Pharmaceutical Co's PS Ratio for today is 4.91.
Good Sign:
Aurisco Pharmaceutical Co Ltd stock PS Ratio (=4.55) is close to 10-year low of 4.55.
The historical rank and industry rank for Aurisco Pharmaceutical Co's PS Ratio or its related term are showing as below:
SHSE:605116'
s PS Ratio Range Over the Past 10 Years
Min: 4.55 Med: 7.49 Max: 12.88
Current: 4.93
During the past 10 years, Aurisco Pharmaceutical Co's highest PS Ratio was 12.88. The lowest was 4.55. And the median was 7.49.
SHSE:605116's PS Ratio is ranked better than 65.52% of 931
companies
in the Biotechnology industry
Industry Median: 8.91
vs SHSE:605116: 4.93
During the past 10 years, Aurisco Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 22.80% per year. The lowest was 7.80% per year. And the median was 16.15% per year.
Aurisco Pharmaceutical Co (SHSE:605116) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aurisco Pharmaceutical Co PS Ratio Related Terms
Aurisco Pharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:605116 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Aurisco Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurisco Pharmaceutical Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aurisco Pharmaceutical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aurisco Pharmaceutical Co's Share Price of today is ¥20.22. Aurisco Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aurisco Pharmaceutical Co (SHSE:605116) has a PS Ratio of 4.91 as of Aug. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aurisco Pharmaceutical Co and its competitors. This is 34% below median its historical median of 7.49. Over the past decade, Aurisco Pharmaceutical Co's PS Ratio has ranged from 4.55 to 12.88. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #321 out of 931 companies in the Biotechnology industry, placing it in the top 34.5%.
Is Aurisco Pharmaceutical Co's PS Ratio too high?
Aurisco Pharmaceutical Co's current PS Ratio of 4.91 is 34% below median its 10-year median of 7.49. Over the past 10 years, this metric has ranged from a low of 4.55 to a high of 12.88. The Biotechnology industry median PS Ratio is 8.91. Aurisco Pharmaceutical Co's value of 4.91 is 44.9% below this industry median. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #321 out of 931 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #321 out of 931 companies for PS Ratio. This puts Aurisco Pharmaceutical Co in the upper half of its industry. The industry median PS Ratio is 8.91. Aurisco Pharmaceutical Co's value of 4.91 is 44.9% below this benchmark. Historically, Aurisco Pharmaceutical Co's own PS Ratio has ranged from 4.55 to 12.88 over the past decade. While the company's 10-year median is 7.49 vs. the industry median of 8.91, Aurisco Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.91, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurisco Pharmaceutical Co's current PS Ratio of 4.91 is 44.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aurisco Pharmaceutical Co and its competitors. For the Biotechnology industry, the median PS Ratio is 8.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurisco Pharmaceutical Co's current PS Ratio is 4.91, which is 34% below median its own 10-year median of 7.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥29.10, compared to a current price of ¥20.22 — trading 30.5% below its estimated fair value. The current PS Ratio is 4.91, which is 34% below median its 10-year median of 7.49 and 44.9% below the Biotechnology industry median of 8.91. Aurisco Pharmaceutical Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current PS Ratio is 4.91 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥20.22 is trading 30.5% below its estimated GF Value™ of ¥29.10.
GuruFocus considers Aurisco Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:605116:
PS Ratio: 4.91 (34% below median its 10-year median of 7.49)
GF Value™: ¥29.10 vs. price of ¥20.22 (30.5% below fair value)
Industry Position: 44.9% below the Biotechnology median (#321 of 931)
No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
79GF Score
Get the complete analysis for SHSE:605116
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605116 has been successfully added to your 
